Pharmacological reactivation of mutant p53: From protein structure to the cancer patient

Oncogene

Volumn 29, Issue 30, 2010, Pages 4245-4252

  Wiman, K G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

apoptosis; cancer therapy; drug discovery; mutant p53; reactivation

Indexed keywords

2,2 BIS(HYDROXYMETHYL) 1 AZABICYCLOOCTAN 3 ONE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; APR 246; CISPLATIN; DNA; DOXORUBICIN; GEFITINIB; IMATINIB; MUTANT PROTEIN; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1; PHIKAN083; PLANT EXTRACT; PRIMA 1; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL DEATH; CELL GROWTH; DNA BINDING; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; GROWTH INHIBITION; HUMAN; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DNA BINDING; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955175360     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.188     Document Type: Review

References (55)

1. Bartek J, Bartkova J, Lukas J. (2007). DNA damage signalling guards against activated oncogenes and tumor progression. Oncogene 26: 7773-7779.
2. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
3. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. (2008). Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105: 10360-10365.
4. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
5. Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288.
6. Bykov VJN, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J et al. (2005a). Restoration of tumor suppressor function to mutant p53 in human tumor cells by a maleimide analog. J Biol Chem 280: 30384-30391.
7. Bykov VJN, Lambert JMR, Hainaut P, Wiman KG. (2009). Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 8: 2509-2517.
8. MET synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24: 3484-3491.
9. Chipuk JE, Maurer U, Green DR, Schuler M. (2003). Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4: 371-381.
10. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumori-genic mutations. Science 265: 346-355.
11. Donehower LA, Lozano G. (2009). 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9: 831-841.
12. Foster BA, Coffey HA, Morin MJ, Rastinejad F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510.
13. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874-1887.
14. Green DR, Kroemer G. (2009). Cytoplasmic functions of the tumour suppressor p53. Nature 458: 1127-1130.
15. Gorgoulis VG, Vassiliou LVF, Karakaidos P, Zacharators P, Kotsinas A, Liloglou T et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913. (Pubitemid 40559004)
16. Hainaut P, Wiman KG (eds). (2005). 25 Years of p53 Research. Springer: Dordrecht. ISBN 1-4020-2920-9.
17. Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W et al. (2009). The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther 8: 2186-2193.
18. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328.
19. Joerger AC, Ang HC, Fersht AR. (2006). Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103: 15056-15061.
20. Joerger AC, Fersht AR. (2008). Structural biology of the tumor suppressor p53. Annu Rev Biochem 77: 557-582.
21. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B et al. (1999). Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 96: 9112-9117.
22. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670.
23. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. (2008). Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454-463.
24. Lambert JMR, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J et al. (2009). PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15: 376-388.
25. MET induces multiple signalling pathways converging on apoptosis. Oncogene 29: 1329-1338.
26. Martins CP, Brown-Swigart L, Evan GI. (2006). Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334.
27. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590.
28. Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F et al. (2003). Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22: 3645-3654.
29. Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
30. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG et al. (2004). Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 127: 285-291.
31. Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G et al. (2006). PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 132: 230-236.
32. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. (2002). Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 33: 181-188.
33. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
34. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
35. Peng Y, Li C, Chen L, Sebti S, Chen J. (2003). Rescue of mutant p53 transcription function by ellipticine. Oncogene 22: 4478-4487.
36. Rippin TM, Bykov VJN, Freund SMV, Selivanova G, Wiman KG, Fersht AR. (2002). Characterization of the p53 rescue drug CP-31398 in vitro and in living cells. Oncogene 21: 2119-2129.
37. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105: 3933-3938.
38. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD. (2001). Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. Pharmacol Exp Ther 297: 1067-1073.
39. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG. (2008). PRIMA-1MET induces mitochondrial apoptosis via activation of caspase-2. Oncogene 27: 6571-6580.
40. Sherr CJ, Weber JD. (2000). The ARF/p53 pathway. Curr Opin Genet Dev 10: 94-99.
41. Shi LM, Myers TG, Fan Y, O'Connor PM, Paull KD, Friend SH et al. (1998). Mining the national cancer institute anticancer drug discovery database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol 53: 241-251.
42. Sigal A, Rotter V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793.
43. Soussi T, Wiman KG. (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312.
44. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
45. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
46. Vousden KH, Lu X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
47. Vousden KH, Prives C. (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
48. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. (2003). Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23: 2171-2181.
49. Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B et al. (2008). A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 15: 718-729.
50. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. (2003). CP-31398, a novel p53-stabilizing agent, induces p53 dependent and p53-independent glioma cell death. Oncogene 22: 8233-8245.
51. Wiman KG. (2006). Strategies for therapeutic targeting of the 53 pathway in cancer. Cell Death Differ 13: 921-926.
52. Xu D, Qian W, Gruber A, Bjorkholm M, Chen Z, Zaid A et al. (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19: 5123-5133.
53. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
54. Zache N, Lambert JMR, Rokaeus N, Shen J, Hainaut P, Bergman J et al. (2008a). Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2: 70-80.
55. Zache N, Lambert JM, Wiman KG, Bykov VJ. (2008b). PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 30: 411-418.